Transdermal hormone therapy and the risk of stroke and venous thrombosis

Climacteric

Volumn 13, Issue 5, 2010, Pages 429-432

  Speroff, L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

hormone therapy; postmenopause; stroke; Transdermal; venous thrombosis

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN;

ADULT; BODY COMPOSITION; BODY SIZE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG RESPONSE; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; GENERAL PRACTICE; HEART MUSCLE ISCHEMIA; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; POPULATION RESEARCH; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; RECALL BIAS; REVIEW; RISK FACTOR; STANDARD; STROKE; UNITED KINGDOM; VEIN THROMBOSIS;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; AGED; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; EVIDENCE-BASED MEDICINE; FEMALE; GREAT BRITAIN; HUMANS; MENOPAUSE; MIDDLE AGED; PROGESTINS; REGRESSION ANALYSIS; RISK FACTORS; STROKE; VENOUS THROMBOSIS; WOMEN'S HEALTH;

EID: 77956165878     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2010.507111     Document Type: Review

References (22)

1. Renoux C, Dell'Aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340: c2519.
2. Scarabin PY, Oger E, Plu-Bureau G, et al. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-432
3. Canonico M, Oger E, Conard J, et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemos 2006;4:1259-1265
4. Straczek C, Oger E, Yon de Jonage-Canonico MB, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005;112:3495-3500
5. Canonico M, Fourier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340-345
6. Renoux C, Dell'aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: population-based study. J Thromb Haemos 2010;March. Epub ahead of print.
7. Lowe GD, Upton MN, Rumley A, McConnachie A, O'Reilly DS, Watt GC. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI, and C-reactive protein-a crosssectional population survey. Thromb Haemost 2001;86: 550-556
8. Post MS, Christella M, Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscl Thromb Vasc Biol 2003;23:1116-1121
9. Løkkegaard E, Jovanovic Z, Heitmann BL, et al. Increased risk of stroke in hypertensive women using hormone therapy. Analyses based on the Danish Nurse Study. Arch Neurol 2003;60:1379-1384
10. Li C, Engström G, Hedblad B, Berglund G, Janzon L. Risk of stroke and hormone replacement therapy. A prospective cohort study. Maturitas 2006;54:11-18.
11. Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008;168:861-866
12. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RL. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345: 1243-1249
13. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-2684
14. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288: 321-333
15. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1707-1712
16. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006;113:2425-2434
17. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477
18. Gavaler JS. Thoughts on individualizing hormone replacement therapy based on the postmenopausal health disparities study data. J Women's Health 2003;12:757-768
19. Kraemer GR, Kraemer RR, Ogden BW, Kilpatrick RE, Gimpel TL, Castracane VD. Variability of serum estrogens among postmenopausal women treated with the same transdermal estrogen therapy and the effect on androgens and sex hormone binding globulin. Fertil Steril 2003;79: 534-542
20. Bukowska H, Stanosz S, Zochowska E, et al. Does the type of hormone replacement therapy affect lipoprotein(a), homocysteine, and C-reactive protein levels in postmenopausal women? Metabolism 2005;54:72-78
21. Ropponen A, Aittomaki K, Vihma V, Tikkanen MJ, Ylikorkala O. Effects of oral and transdermal estradiol administration on levels of sex hormone-binding globulin in postmenopausal women with and without a history of intrahepatic cholestasis of pregnancy. J Clin Endocrinol Metab 2005;90:3431-3434
22. Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619-25